[
  {
    "ts": null,
    "headline": "Earnings live: Wayfair stock soars following Q3 results, PayPal rises, Royal Caribbean slides",
    "summary": "Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
    "url": "https://finnhub.io/api/news?id=6062b56a91ddcba739e6af9599195a7f9b6ed2e993c1d2aa553a62f1b23d2e9c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761685288,
      "headline": "Earnings live: Wayfair stock soars following Q3 results, PayPal rises, Royal Caribbean slides",
      "id": 137243117,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
      "url": "https://finnhub.io/api/news?id=6062b56a91ddcba739e6af9599195a7f9b6ed2e993c1d2aa553a62f1b23d2e9c"
    }
  },
  {
    "ts": null,
    "headline": "Buy, Sell or Hold MRK Stock Ahead of Q3 Earnings? Things to Know",
    "summary": "MRK faces pressure from weak vaccine sales and rising competition, but strong oncology growth and new launches could support a rebound.",
    "url": "https://finnhub.io/api/news?id=c59977d629be90dfa5414d1c82c1ee5dab700969b25f3f1cb55902e3ea7c0ed7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761669420,
      "headline": "Buy, Sell or Hold MRK Stock Ahead of Q3 Earnings? Things to Know",
      "id": 137243529,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "MRK faces pressure from weak vaccine sales and rising competition, but strong oncology growth and new launches could support a rebound.",
      "url": "https://finnhub.io/api/news?id=c59977d629be90dfa5414d1c82c1ee5dab700969b25f3f1cb55902e3ea7c0ed7"
    }
  },
  {
    "ts": null,
    "headline": "3 Cancer-Focused Stocks Showing Strong Pipeline Progress",
    "summary": "Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.",
    "url": "https://finnhub.io/api/news?id=8563a14a3ef258858ea8c55d378e17f5312e20744e165be336f0e7dd071263c1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761665700,
      "headline": "3 Cancer-Focused Stocks Showing Strong Pipeline Progress",
      "id": 137243278,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.",
      "url": "https://finnhub.io/api/news?id=8563a14a3ef258858ea8c55d378e17f5312e20744e165be336f0e7dd071263c1"
    }
  },
  {
    "ts": null,
    "headline": "As Dow Hits Record, High-Yield Dogs of the Dow Still a Bargain",
    "summary": "Since the turn of the century, the Dogs of the Dow have significantly outperformed the overall market. These five are perfect plays for a slowing economy.",
    "url": "https://finnhub.io/api/news?id=dd39d90364f8171177018c77bbce3a9c9f608bfc4db00c04645733ec75563b90",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761660825,
      "headline": "As Dow Hits Record, High-Yield Dogs of the Dow Still a Bargain",
      "id": 137237769,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Since the turn of the century, the Dogs of the Dow have significantly outperformed the overall market. These five are perfect plays for a slowing economy.",
      "url": "https://finnhub.io/api/news?id=dd39d90364f8171177018c77bbce3a9c9f608bfc4db00c04645733ec75563b90"
    }
  },
  {
    "ts": null,
    "headline": "The Bottom Fishing Club - Organon: Deep Value In Drugs/Medical Products",
    "summary": "Organon stock plunged after CEO's exit and audit probe. Discover if its low valuation, global portfolio, and earnings catalysts make it a buy now.",
    "url": "https://finnhub.io/api/news?id=cf489c10d6d73c61b67e2899cb8f6f0e7b09d7f579ed86a83537732afa102807",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761660375,
      "headline": "The Bottom Fishing Club - Organon: Deep Value In Drugs/Medical Products",
      "id": 137240047,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1940034961/image_1940034961.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Organon stock plunged after CEO's exit and audit probe. Discover if its low valuation, global portfolio, and earnings catalysts make it a buy now.",
      "url": "https://finnhub.io/api/news?id=cf489c10d6d73c61b67e2899cb8f6f0e7b09d7f579ed86a83537732afa102807"
    }
  },
  {
    "ts": null,
    "headline": "Earnings live: PayPal stock soars on OpenAI partnership, UPS surges, UnitedHealth pops",
    "summary": "Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
    "url": "https://finnhub.io/api/news?id=03478b2a3192dd5351ec42e918225c7acf20b105dcff53cdb59916bfda786d78",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761653093,
      "headline": "Earnings live: PayPal stock soars on OpenAI partnership, UPS surges, UnitedHealth pops",
      "id": 137237611,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
      "url": "https://finnhub.io/api/news?id=03478b2a3192dd5351ec42e918225c7acf20b105dcff53cdb59916bfda786d78"
    }
  },
  {
    "ts": null,
    "headline": "Merck kidney cancer drug succeeds in two large trials",
    "summary": "The results could help expand use of Welireg, one of the medicines Merck is counting on to drive revenue growth when its top-selling immunotherapy Keytruda loses patent protection.",
    "url": "https://finnhub.io/api/news?id=d66a847c8a0ee35fa7036f6fc01cfb51a5594356a35c02233d48d18064e3e5fe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761652860,
      "headline": "Merck kidney cancer drug succeeds in two large trials",
      "id": 137243531,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The results could help expand use of Welireg, one of the medicines Merck is counting on to drive revenue growth when its top-selling immunotherapy Keytruda loses patent protection.",
      "url": "https://finnhub.io/api/news?id=d66a847c8a0ee35fa7036f6fc01cfb51a5594356a35c02233d48d18064e3e5fe"
    }
  },
  {
    "ts": null,
    "headline": "Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer",
    "summary": "Karen Smith, MD, PhD, MBA, LLM, joins with over 25 years of global pharma and biotech experience, having contributed to more than 20 regulatory approvals Dr Smith's appointment will accelerate Step Pharma's ‘pipeline in a product’ strategy, leveraging her clinical and regulatory expertise to advance dencatistat, afirst-in-class CTPS1 inhibitor across multiple cancer and blood disorder indicationsAppointment follows Step Pharma’s recently announced €38 million Series C financing Saint-Genis-Pouil",
    "url": "https://finnhub.io/api/news?id=35309bf903f94a702a0cf3bbc6528f5a442db9d39d3f3bf37d15e05b697b0991",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761652800,
      "headline": "Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer",
      "id": 137237854,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Karen Smith, MD, PhD, MBA, LLM, joins with over 25 years of global pharma and biotech experience, having contributed to more than 20 regulatory approvals Dr Smith's appointment will accelerate Step Pharma's ‘pipeline in a product’ strategy, leveraging her clinical and regulatory expertise to advance dencatistat, afirst-in-class CTPS1 inhibitor across multiple cancer and blood disorder indicationsAppointment follows Step Pharma’s recently announced €38 million Series C financing Saint-Genis-Pouil",
      "url": "https://finnhub.io/api/news?id=35309bf903f94a702a0cf3bbc6528f5a442db9d39d3f3bf37d15e05b697b0991"
    }
  },
  {
    "ts": null,
    "headline": "Does FDA’s Broader WINREVAIR Approval Strengthen Merck’s (MRK) Cardio-Pulmonary Pipeline Narrative?",
    "summary": "On October 27, 2025, Merck announced that the FDA approved an expanded label for WINREVAIR (sotatercept-csrk), allowing its use in adults with pulmonary arterial hypertension (PAH) to improve exercise capacity, functional class, and reduce risks of hospitalization, lung transplantation, and death. This regulatory milestone for WINREVAIR, supported by the Phase 3 ZENITH trial, highlights Merck's continued progress in broadening the clinical impact of its cardio-pulmonary portfolio. Next,...",
    "url": "https://finnhub.io/api/news?id=3648e3ef65b4de0ba678a27c7a78a9f3632b7be6d7d3b4330eced531c1fa6546",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761649825,
      "headline": "Does FDA’s Broader WINREVAIR Approval Strengthen Merck’s (MRK) Cardio-Pulmonary Pipeline Narrative?",
      "id": 137237856,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "On October 27, 2025, Merck announced that the FDA approved an expanded label for WINREVAIR (sotatercept-csrk), allowing its use in adults with pulmonary arterial hypertension (PAH) to improve exercise capacity, functional class, and reduce risks of hospitalization, lung transplantation, and death. This regulatory milestone for WINREVAIR, supported by the Phase 3 ZENITH trial, highlights Merck's continued progress in broadening the clinical impact of its cardio-pulmonary portfolio. Next,...",
      "url": "https://finnhub.io/api/news?id=3648e3ef65b4de0ba678a27c7a78a9f3632b7be6d7d3b4330eced531c1fa6546"
    }
  },
  {
    "ts": null,
    "headline": "Merck Announces KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy",
    "summary": "RAHWAY, N.J.,, October 28, 2025--Merck Announces KEYTRUDA Plus WELIREG Met Primary Endpoint of DFS in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy",
    "url": "https://finnhub.io/api/news?id=1f73d4f7fd162a3e17781ab6cc1dd159c044b1b6b4ee10404b6d977572f2d8de",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761648300,
      "headline": "Merck Announces KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy",
      "id": 137237857,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J.,, October 28, 2025--Merck Announces KEYTRUDA Plus WELIREG Met Primary Endpoint of DFS in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy",
      "url": "https://finnhub.io/api/news?id=1f73d4f7fd162a3e17781ab6cc1dd159c044b1b6b4ee10404b6d977572f2d8de"
    }
  },
  {
    "ts": null,
    "headline": "Top Pharmaceutical Companies Shaping The Future Of Healthcare",
    "summary": "Aging populations and clearer U.S. drug pricing boost long-term pharma outlook. Leaders like Eli Lilly and Merck lead in GLP-1s, oncology, and pipeline strength.",
    "url": "https://finnhub.io/api/news?id=d8552c40676d75188ca76593380e6229d38d1c1093cfb419146ba101bc053f8c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761648180,
      "headline": "Top Pharmaceutical Companies Shaping The Future Of Healthcare",
      "id": 137238505,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1349026574/image_1349026574.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Aging populations and clearer U.S. drug pricing boost long-term pharma outlook. Leaders like Eli Lilly and Merck lead in GLP-1s, oncology, and pipeline strength.",
      "url": "https://finnhub.io/api/news?id=d8552c40676d75188ca76593380e6229d38d1c1093cfb419146ba101bc053f8c"
    }
  },
  {
    "ts": null,
    "headline": "Merck and Eisai Announce WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma",
    "summary": "RAHWAY, N.J. & NUTLEY, N.J., October 28, 2025--Merck and Eisai Announce WELIREG® Plus LENVIMA® Met Primary Endpoint of PFS in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma",
    "url": "https://finnhub.io/api/news?id=e513ddb23fb838a86d8fedddbb0202e0cd24c2e0dc99c8002c9d0eb3fc923319",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761647400,
      "headline": "Merck and Eisai Announce WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma",
      "id": 137237858,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J. & NUTLEY, N.J., October 28, 2025--Merck and Eisai Announce WELIREG® Plus LENVIMA® Met Primary Endpoint of PFS in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma",
      "url": "https://finnhub.io/api/news?id=e513ddb23fb838a86d8fedddbb0202e0cd24c2e0dc99c8002c9d0eb3fc923319"
    }
  },
  {
    "ts": null,
    "headline": "Incyte trims pipeline; Zenas surges on MS drug results",
    "summary": "Incyte axed three prospects to focus on “high-value programs,” its CEO said. Elsewhere, MapLight priced an IPO during the federal government shutdown and GSK picked up a cancer drug.",
    "url": "https://finnhub.io/api/news?id=75116b93fa5661d994e1d8c80f01804b56bfa02ab03a758a4536965f66e3086b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761645600,
      "headline": "Incyte trims pipeline; Zenas surges on MS drug results",
      "id": 137237859,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Incyte axed three prospects to focus on “high-value programs,” its CEO said. Elsewhere, MapLight priced an IPO during the federal government shutdown and GSK picked up a cancer drug.",
      "url": "https://finnhub.io/api/news?id=75116b93fa5661d994e1d8c80f01804b56bfa02ab03a758a4536965f66e3086b"
    }
  }
]